Cambium Bio Limited has released a press release.
Cambium Bio Signs US$2.0M plus Licensing Deal
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- FY25 Appendix 4E and Annual Report
- Placement Participant Update
- Cambium Bio Raises A$2.12 million
- Half Year Report (December 2024)Cambium Bio Limited Half Year Report (December 2024) (Feb 27, 2025Feb 27, 2025)
- FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
Later from Cambium Bio
- Cambium Bio Signs Strategic MoU with Benta SAS
- Cambium Bio Secures A$2.4 Million Strategic Investment
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report and Accounts
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio